Cornerstone Capital Inc. lifted its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 67.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 145,500 shares of the biotechnology company’s stock after purchasing an additional 58,850 shares during the period. Cornerstone Capital Inc. owned about 0.24% of Viking Therapeutics worth $1,381,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Janney Montgomery Scott LLC acquired a new stake in shares of Viking Therapeutics during the second quarter worth about $114,000. Strs Ohio acquired a new stake in shares of Viking Therapeutics during the second quarter worth about $120,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Viking Therapeutics during the second quarter worth about $144,000. Sio Capital Management LLC increased its position in shares of Viking Therapeutics by 2.1% during the first quarter. Sio Capital Management LLC now owns 1,276,845 shares of the biotechnology company’s stock worth $5,580,000 after purchasing an additional 26,595 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in shares of Viking Therapeutics during the first quarter worth about $140,000. Institutional investors and hedge funds own 53.80% of the company’s stock.
A number of research firms have recently commented on VKTX. BidaskClub upgraded Viking Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 21st. Laidlaw raised their price target on Viking Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, June 1st. SunTrust Banks began coverage on Viking Therapeutics in a report on Friday, July 20th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright raised their price target on Viking Therapeutics from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, June 1st. Finally, Raymond James began coverage on Viking Therapeutics in a report on Thursday, June 28th. They set an “outperform” rating and a $15.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $14.33.
Shares of VKTX opened at $13.03 on Wednesday. Viking Therapeutics Inc has a twelve month low of $1.05 and a twelve month high of $13.43. The company has a market capitalization of $792.80 million, a price-to-earnings ratio of -16.49 and a beta of 2.86.
Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). equities research analysts forecast that Viking Therapeutics Inc will post -0.44 earnings per share for the current fiscal year.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.